Novavax | NVAX - Ebit


Novavax reported $20.94M in EBIT for its fiscal quarter ending in December of 2025.





Ebit Change Date
Adma Biologics USD 62.75M 13.56M Dec/2025
Agenus USD 14.4M 19.26M Dec/2025
AstraZeneca USD 2.97B 4.48B Dec/2025
BioCryst Pharmaceuticals USD 260.38M 230.79M Dec/2025
Cassava Sciences USD -13.55M 1.69M Dec/2025
Geron USD -10.79M 3.1M Dec/2025
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
MannKind USD -69.24M 28.19M Dec/2025
Merck USD 6.24B 1.32B Dec/2025
Minerva Neurosciences USD -4.37M 1.71M Sep/2024
Moderna USD -857M 597M Dec/2025
Novartis USD 4.06B 413M Dec/2025
Novavax USD 20.94M 100.32M Dec/2025
Pfizer USD 4.65B 71M Dec/2025
Sanofi EUR 1.7B 2.17B Dec/2025
Sarepta Therapeutics USD -410.08M 347.2M Dec/2025
TG Therapeutics USD 50.49M 21.13M Dec/2025